Patricia Van Arnum

Editorial Director, DCAT

patricia@dcat.org
Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members. She is editor of DCAT Value Chain Insights, DCAT’s editorial newsletter providing news and analysis of the business of bio/pharmaceutical development and manufacturing covering the full spectrum of the bio/pharmaceutical manufacturing value chain. She also provides content advisement and support for DCAT’s volunteer committees. Overall, she has more than 25 years of experience covering the Bio/Pharmaceutical, Fine-Chemical and Chemical industries as a business and science editor. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science and holds undergraduate degrees in chemistry, economics, and political science.

LATEST

Manufacturing and Supply Lines: Fine Chemicals
By

By
Rising energy and raw materials costs are two key factors impacting the chemical manufacturing value chain for intermediates and small-molecule APIs. What other key developments and trends are impacting the fine-chemicals market?

Blockbusters of 2022: Who Makes the Mark?
By

By
With more than one month remaining in 2022, which of the bio/pharmaceutical majors are leading the pack with blockbusters (defined as products with sales of $1 billion or more)? DCAT Value Chain Insights takes an inside look.

The CDMO/CMO Report: Parenteral Drugs
By

By
Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain Insights rounds up the latest developments among CDMO/CMOs.  

Bayer Says Energy, Supply Chains Are Top Priorities
By

By
Energy, inflationary pressures, and mitigating supplier risk are high priorities for Bayer. In Germany, the company aims to be independent of Russian gas by the end of the year and says that procurement management and supply chain stability are top priorities.

Cell and Gene Therapies: Expansions by CDMOs and CMOs and Key Trends
By

By
Although cell & gene therapies are a niche product area, the industry as a whole faces limited capacity. Both large and small CDMOs continue to expand manufacturing capacity for cell and gene therapies. Which companies are in the mix and are expanding?

FDA Launches CMC Pilot for Breakthrough & Fast-Tracked Drugs
By

By
The FDA is launching a Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot program to facilitate the expedited review of products with accelerated development timeframes.

The European Chemical Industry Seeks More Action To Combat the Energy Crisis and Mfg Risk in Europe
By

By
The European Chemical Industry Council (Cefic) is calling for more action to address Europe’s energy crisis. For the first time ever, the EU is importing more chemicals than it exports, and Cefic is proposing specific measures to address the energy crisis and the adverse impact on chemical production.

Supplier Metrics: How Can Companies Measure Sustainability in Supply-Chain Performance?
By

By
A recent study by the management consultancy, EY, showed that a majority of supply-chain executives are focused on environmental, social and governance (ESG) initiatives, but lack capabilities to measure supply-chain sustainability. What can be done?

European Generics Industry Seek Reforms to Combat Inflation in API Mfg
By

By
Medicines for Europe, which represents the generic drug industry in Europe, is calling for reforms in medicines procurement and pricing models to include security of supply as a criteria and is asking for further support for pharma manufacturing as a means to combat inflationary pressures in raw materials, transportation, and production.

Environmental Investments Soar But Emissions Targets Fall Short
By

By
A recent analysis by PwC shows that global decarbonization targets are falling short to meet net zero emissions goals, with nine of 20 major economies actually showing increases in carbon intensity over the last year. At the same time, ESG-focused institutional investment is soaring. What’s the disconnect?